Disease characteristics at baseline, and change from baseline at weeks 12, 48, and 96 for all JIA categories.
| Mean (95% CI) Baseline, n = 127 | Mean (95% CI) [% change] | |||
|---|---|---|---|---|
| Week 12, n = 123 | Week 48, n = 119 | Week 96, n = 109 | ||
| PGA of disease activitya | 5.0 (4.7, 5.3) | 1.5 (1.3, 1.7) [−70.6] | 1.0 (0.8, 1.2) [−80.0] | 0.6 (0.5, 0.8) [−87.7] |
| Patient/parent global assessment | 5.0 (4.6, 5.4) | 2.2 (1.9, 2.5) [−50.2] | 1.7 (1.3, 2.0) [−66.1] | 1.0 (0.7, 1.2) [−80.1] |
| No. active joints | 6.7 (5.9, 7.6) | 1.7 (1.3, 2.2) [−73.0] | 0.9 (0.5, 1.2) [−86.0] | 0.6 (0.2, 1.0) [−90.8] |
| No. joints with LOM | 5.7 (5.0, 6.5) | 1.6 (1.2, 2.0) [−66.9] | 1.3 (0.8, 1.7) [−73.6] | 1.1 (−0.5, 1.6) [−79.1] |
| CRP, mg/lb | 8.3 (5.7, 10.8) | 2.5 (1.2, 3.8) [−22.1] | 2.0 (1.3, 2.8) [−9.9] | 2.8 (1.7, 3.8) [32.6] |
| CHAQ | 0.8 (0.7, 0.9) | 0.3 (0.3, 0.4) [−53.6] | 0.2 (0.2, 0.3) [−69.5] | 0.2 (0.1, 0.2) [−74.2] |
| Parent’s global assessment of child’s pain, VASa | 5.1 (4.6, 5.5) | 2.0 (1.7, 2.4) [−51.9] | 1.5 (1.2, 1.8) [−68.4] | 0.9 (0.6, 1.2) [−79.5] |
| Duration of morning stiffness, min | 73.5 (55.8, 91.2) | 13.3 (5.9, 20.7) [−66.0] | 6.0 (1.7, 10.4) [−71.1] | 5.8 (1.6, 9.9) [−70.2] |
| JADASc | 17.2 (15.9, 18.5) | 5.5 (4.7, 6.4) | 3.6 (2.9, 4.3) | 2.3 (1.7, 2.9) |
| ERA-specific measures | Baseline, n = 38 | Week 12, n = 36 | Week 48, n = 34 | Week 96, n = 30 |
| Prorated tender entheseal score | 5.9 (2.8, 9.0) | 1.8 (−0.3, 3.9) [−57.8] | 1.3 (0.0, 2.6) [−64.0] | 0.3 (−0.1, 0.7) [−79.9] |
| Overall back pain, mm | 25.9 (16.6, 35.3) | 11.8 (5.7, 18.0) [−21.2] | 8.6 (3.1, 14.1) [37.0]* | 2.4 (0.7, 4.1) [−54.1] |
| Nocturnal back pain, mm | 16.4 (7.2, 25.5) | 5.8 (1.8, 9.8) [−6.8] | 5.9 (1.0, 10.7) [5.6]* | 2.2 (0.9, 3.5) [−41.1] |
| Schober test, cmd | 5.0 (4.4, 5.7) | 5.5 (4.8, 6.1) [9.7] | 5.4 (4.8, 5.9) [12.3] | 5.3 (4.7, 6.0) [7.5] |
| PsA-specific measures | Baseline, n = 29 | Week 12, n = 29 | Week 48, n = 28 | Week 96, n = 25 |
| Psoriasis BSA, % | 9.8 (4.7, 15.0) | 3.5 (1.3, 5.7) [−45.0] | 3.1 (0.0, 6.3) [−48.3] | 1.1 (−0.3, 2.0) [−54.4] |
| PGA of psoriasise | 1.8 (1.2, 2.3) | 0.8 (0.5, 1.1) [−35.9] | 0.8 (0.4, 1.1) [−44.0] | 0.5 (0.1, 0.8) [−55.1] |
↵* Positive mean % change at some visits is due to outlier values.
↵a n = 108 for Week 96.
↵b n = 120, 117, and 103 for weeks 12, 48, and 96, respectively.
↵c n = 118, 120, 117, and 102 for baseline and weeks 12, 48, and 96, respectively.
↵d Modified Schober test values in the table were subtracted 10 from reported values.
↵e n = 28 for Week 12. BSA: body surface area; CHAQ: Childhood Health Assessment Questionnaire; CRP: C-reactive protein; ERA: enthesitis-related arthritis; JADAS: juvenile arthritis disease activity score; JIA: juvenile idiopathic arthritis; LOM: limitation of motion; PGA: physician’s global assessment; PsA: psoriatic arthritis; VAS: visual analog scale.